Abstract Background/purpose: In this study, we evaluated the effectiveness of oral uracil etegafur (UFUR) as a postoperative adjuvant treatment for patients with advanced oral squamous cell carcinoma (OSCC). Materials and methods: The study cohort consisted 80 patients with advance cancer treated between January 2003 and December 2007. Half of the patients received oral UFUR as postoperative metronomic adjuvant chemotherapy, while the other half received no treatment. No patients received postoperative radiotherapy or other systemic chemotherapy. Disease-free survival and toxicity were evaluated in these two groups. Twenty-two patients were assessed pre-and postoperatively for viable circulating endothelial progenitor cells using flow cytometry. Results: The disease-free survival rates at 4 years were 84.6% with oral UFUR treatment and 60.9% without UFUR therapy (P Z 0.02). The toxicity and disease progression profiles did not differ significantly between the two groups, but viable circulating endothelial progenitor cell counts decreased after the administration of oral UFUR. Advanced OSCC patients who received oral UFUR had a better prognosis than those who did not. Conclusion: Oral UFUR is a promising postoperative metronomic adjuvant chemotherapy regimen for advanced OSCC.
Introduction
Oral squamous cell carcinoma (OSCC) is the fourth major cause of mortality among men in Taiwan, and its incidence continues to rise annually. 1 According to analyses conducted by the Department of Oral and Maxillofacial Surgery of Mackay Memorial Hospital, Taipei, Taiwan the postoperative overall 5-year survival rate for OSCC is 65.45%, and > 85% of patients with stage I and II OSCC survive for at least 5 years after the treatment.
2 However, the survival rate was found to be < 50% in stage IV patients. Survival rates are particularly low in patients with cervical lymph node metastasis.
Most patients with newly diagnosed OSCC are already in a late stage of disease, and large tumors are associated with a higher local recurrence rate. Field cancerization has been proposed as the main cause of recurrence and second primary cancers among patients who have undergone advanced resection. 3 Postoperative adjuvant treatment involves eradication of these microtumors to prevent them from recurring locally. The National Comprehensive Cancer Network (NCCN) guideline V2 2014 states that surgery is the preferable treatment for oral cavity cancer (http://www. nccn.org/professionals/physician_gls/f_guidelines.asp). Con sequently, radiotherapy, chemotherapy, or a combination of both is usually administered after surgery. However, some patients refuse, and older patients (! 70 years) may not be able to tolerate, postoperative radiotherapy; in these cases, postoperative chemotherapy may improve treatment outcomes. Several randomized clinical trials on gastric, lung, colon, and breast cancers have indicated that postoperative adjuvant treatments can significantly improve survival rates. 4 Other studies have shown that intravenous postoperative chemotherapy with cisplatin combined with 5-fluorouracil (5-FU) improved the survival of patients with advanced stage cancers or cervical metastasis. 5 However, it has been shown that the recommended doses often have severe side effects and can even cause sudden death. 5 Therefore, orally administered low-dose chemotherapy agents such as fluoropyrimidines, uraciletegafur (UFUR), capecitabine, and fluoropyrimidines have been recently developed. Chemotherapeutic agents are administered orally, both for convenience and to increase patient compliance. Advantages of oral chemotherapeutic agents have been shown to include a reduction in acute toxicities such as high grade myelosuppression, vomiting, nausea, and mucositis, 6 and sometimes surprisingly good activity against drug-resistant tumors. 7 However, a disadvantage of oral chemotherapy is that patients cannot be monitored closely and therefore may continue with cytotoxic therapy without appropriate medical support. As a result, communication with patients regarding drug-related issues and intensive outpatient follow-up are of considerable importance. 8 Oral administration is generally safer than the intravenous delivery of chemotherapeutic-agents. Several studies assessed the use of oral chemotherapeutic agents in the postoperative adjuvant treatment of different malignancies including lung, breast, colon, and rectal cancer. 9e11 One of these was a prospective randomized study of postoperative oral chemotherapy with levamisole and UFUR for the treatment of head and neck cancer. A trend towards better distant control in postoperative oral chemotherapy patients was observed, and toxic side effects were minimal in the study group. 12 In this study, we assessed the use of oral UFUR only as a metronomic chemotherapy in advanced OSCC patients who refused postoperative adjuvant radiotherapy, and analyzed the survival rate and adverse effects in these patients.
Materials and methods
The study cohort comprised patients treated in the Department of Oral and Maxillofacial Surgery, Mackay Memorial Hospital, between January 2003 and December 2007 who were diagnosed with OSCC by histopathology. Patients with a previous history of malignancy, or who were immunocompromised, were excluded from analysis. The study patients received their initial treatments in our hospital and had not undergone surgical resection, radiotherapy, or chemotherapy in other hospitals. Computed tomography, 99 Tc whole body bone scans, chest radiograms, and wholeabdomen echograms were used for clinical staging. The study cohort included 80 patients with advanced OSCC who had undergone tumor resection and cervical lymph node dissection. The final diagnosis was dependent on the histopathological results and the AJCC (7 th edition) tumor classification. The inclusion criterion was primary T3eT4 tumors without cervical lymphatic metastasis or primary T2-T3 tumors with N1 cervical lymph node metastasis. Patients who had positive surgical margin or extracapsular lymph node spread were excluded from the study. All of the patients had refused postoperative radiotherapy and were notified of the risks and side effects associated with chemotherapy.
The patients were randomly divided into two groups as follows: 40 patients received orally administered UFUR 4 weeks after surgery as an adjuvant metronomic chemotherapy at a dose of 150 mg/m 2 /d, twice daily for 12 months. During the follow-up period visits were conducted on a regular basis, hematology laboratory tests and serum profile tests were performed every 3 rd month, and medical imaging including computed tomography, chest radiography, whole abdomen echography, and 99 Tc whole body bone scans were conducted every 4 months to exclude locoregional recurrence or distant metastasis. In addition, 22 patients who received oral UFUR were randomly selected to have their blood tested to determine the number of circulating endothelial cells (CECs) and circulating endothelial progenitor (CEP) cells both prior to and after chemotherapy. All the patients signed the informed consent form after approval by the Institutional Review Board (Mackay Memorial Hospital). Statistical analyses were performed to determine the significance of differences in overall survival rates, toxicity and the number of CEP cells between the two groups.
CECs and CEP cell evaluation by flow cytometry CEC and CEP cell counts were evaluated in all patients as previously described. In brief, fresh blood samples were immunostained for anti-CD45 (to exclude hematopoietic cells), anti-CD31 (an endothelial marker; BD Biosciences), anti-CD133 (a progenitor cell marker; MACS), anti-CD146 (an endothelial cell marker; Millipore) and the apoptosis marker 7-aminoactinomycin D (Merck). Red blood cells were lysed in red cell lysis buffer and viable and apoptotic CECs and CEP cells were analyzed by fluorescenceactivated cell sorting (BD Biosciences). CECs were defined as being negative for the hematopoietic marker CD45 and the progenitor marker CD133, and positive for the endothelial markers CD146 and CD31. CEP cells were identified by the expression of CD133. 13 
Statistical analysis
The Student t test, Chi-squared test, and Fisher's exact test were used to compare the various clinical variables between the two groups. Disease-free survival rates were analyzed using the KaplaneMeier method, and the ManneWhitney U pairs test was employed to analyze changes in the number of CEP cells prior to and after therapy. The Cox proportional hazards regression model was used to identify statistically significant variables related to survival. Statistical significance was defined as P < 0.05.
Results
The clinical data of these patients is summarized in Table 1 . Patients who received UFUR treatment had a survival rate of 84.6%, while those who did not had a survival rate of 60.9%. KaplaneMeier analysis indicated that patients treated with UFUR had longer progression-free survival (Fig. 1) . Locoregional recurrence accounted for a large proportion of treatment failure (Table 1) . Of the patients receiving orally administered UFUR, 2.5% experienced neutropenia, 2.5% had anemia, 2.5% had nausea and vomiting, and 5% had an erythematous skin rash; the frequencies of these events did not differ significantly from those in the control group (Table 2) . Cox regression models indicated that oral UFUR was an independent risk factor for ( Table 3 ). Eighteen of the 22 patients receiving orally administered UFUR showed a reduction in the number of viable CEP cells (80.9%; Fig. 2) , and there was a statistically significant decrease in the number of viable CEP cells after treatment (Fig. 3) . Of the three patients whose viable CEPs did not reduce after UFUR treatment, two died due to the locoregional failure, and the other survived without recurrence. However, these differences were not statistically significant, probably due to the small number of cases.
Discussion
5-FU was first synthesized by Heidelberger et al. 14 The anticancer mechanism of 5-FU lies in its inhibition of thymidylate synthase, reducing the synthesis of thymidylate and subsequently, the synthesis of DNA and RNA. It has become the most commonly used anticancer agent, and is widely administered to treat gastric, colorectal, pancreatic, and breast cancer. 6e8 The absorption of orally administered 5-FU is very poor because it is rapidly degraded by dihydropyrimidine dehydrogenase (DPD) in the intestine. Therefore, in order to maintain concentrations of 5-FU in the blood, continuous intravenous infusion is used. Orally administered agents with better absorption have been developed. Tegafur is the precursor of 5-FU, and its Months after operation Survival % Figure 1 KaplaneMeier survival curves for patients who received postoperative oral uraciletegafur (UFUR) therapy versus the control group. The disease-free survival rates at 48 months were 85.6% for the oral UFUR group and 75.9% for the control group. The P values were calculated using the stratified log-rank test. administration results in the prolonged elevation of blood 5-FU levels. It is slowly converted to 5-FU through the P-450 enzyme system and thymidine phosphorylase in tumor tissues. 6 Uracil itself is a component of nucleic acids, and has neither pharmaceutical efficacy nor toxicity. It is a natural pyrimidine that must be metabolized by DPD; it can thus compete with 5-FU for DPD, thereby slowing down its degradation and extending its effective duration and availability. 6, 15 A number of clinical trials have shown that orally administered UFUR adjuvant chemotherapy is effective. 15 Some reports compared the results of orally administered UFUR/leucovorin combination with intravenously injected 5-FU/leucovorin and concluded that they had similar efficacies, although oral administration resulted in fewer side effects. 16 In this study, we administered oral UFUR as a postoperative adjuvant treatment for OSCC. The disease-free survival rate was w9% higher than that of untreated patients, indicating that 5-FU can control OSCC effectively via oral administration. Metronomic chemotherapy is the continuous administration of pharmaceutical agents at low doses but at short, regular intervals (daily, several times/wk, or weekly) in order to maintain their blood concentrations and to repress tumor angiogenesis. The dosage is usually much lower than the conventional maximum tolerable dose, reducing the need to suspend treatment compared to conventional chemotherapy. Metronomic chemotherapy does not attack tumors; rather, it blocks the formation of new tumorderived blood vessels to cut off the supply of nutrients required for tumor growth. 17 Patil et al. 18 reported the effectiveness and toxicity of a metronomic chemotherapy regimen with a palliative intent in head and neck cancers. They found only minimal toxicity, and that the median progression-free and overall survival were 153 days and 186 days, respectively. They concluded that metronomic chemotherapy is well tolerated and has a potential role in the palliative treatment of head and neck cancer. Metronomic chemotherapy is not only less toxic but also maintains long-term cytotoxicity against cancer cells in the blood, thereby avoiding the sanctuary effect arising from the uneven concentrations of agents, reducing drug resistance and side effects. 18 Browder et al 7 reported that low-dose injection of cyclophosphamide inhibits tumor growth in mice, causing endothelial apoptosis and reduced angiogenesis, and Bocci et al 19 found that metronomic chemotherapy boosts could knock out THBS1 and obstruct angiogenesis. Kieran et al 20 reported that when 20 patients who were nonresponsive to surgery, radiotherapy, and conventional chemotherapy were orally administered low doses of thalidomide, celecoxib, and cyclophosphamide for 6 months, a significant increase in disease-free survival rates was observed after 2.5 years. Several clinical trials have confirmed the effectiveness of metronomic chemotherapy, in malignancies, such as breast, lung, gastric, and colon cancer. 21 The present study applies the concepts of metronomic chemotherapy to the oral administration of UFUR to OSCC patients. The dose of tegafur used in conventional oral UFUR treatment is 300 mg/m 2 /d. Based on a study by Kerbel et al, 8 we used 150 mg of tegafur twice daily for 1 year. 20 This dose was relatively low compared to that used in conventional treatment. After long follow-up period, the disease-free survival rate was significantly higher than that of control group. The results suggest that low dose metronomic chemotherapy is an effective adjuvant therapy in treating oral cancer.
The side effects of long-term administration of oral UFUR are similar to those seen with intravenous injection of 5-FU, and are related to the daily dose and duration of treatment. The most common side effects are gastrointestinal disorders such as nausea, vomiting, and diarrhea, bone marrow inhibition leading to leucopenia, thrombocytopenia, and anemia, and liver damage leading to acute hepatitis, pigmentation, and red and dried scars on the hands (handefoot syndrome). Cautious and regular monitoring of the blood, liver, and kidneys is required. It has been reported that orally administered UFUR and UFUR combined with leucovorin causes fewer side effects. 4 In this study, we observed that only one patient developed neutropenia, one patient had anemia, one patient experienced nausea and vomiting, and two patients developed cutaneous eruptions. The fraction of patients experiencing side effects did not differ significantly between the UFUR treated and control groups. In comparison to previous studies using conventional chemotherapy with intravenous 5-FU, there seemed to be far fewer side effects in our study. Thus, oral UFUR appears to be better tolerated.
Under normal circumstances, angiogenesis occurs during wound repair and the menstruation; pathological angiogenesis occurs in some disease processes, including diabetic retinopathy, degenerative arthritis, and cancer. 22 Hladovec and Rossman first found increased numbers of CECs and endothelial progenitor cells (EPCs) in cancer patients. 23 EPCs are a subgroup of vascular progenitor cells found in bone marrow and its blood supply. They are capable of differentiating into vascular endothelial cells and are rarely found in healthy people. EPCs enter the bloodstream from the bone marrow, differentiation into vascular endothelial cells, and facilitate tumor angiogenesis. 24 In animal experiments, Duda et al 25 found that bone-marrow derived CEP cells were involved in tumor angiogenesis, and Shaked et al 26 also found that CEP cells were rapidly mobilized by agents that disrupt the vasculature and developed into tumor rims in mouse models. Tumor rims shrink and blood flow is reduced after the administration of agents that inhibit CEP cells, proving that they play an important role in angiogenesis. Thus, the presence of CEP cells and EPCs can serve as indicators to assess and predict the effectiveness of chemotherapy, 27 and quantifying CEP cells is one of the methods used to assess the effectiveness of treatments. 28 There was a significant reduction in CEPs in our patients after the oral administration of UFUR, which may explain why metronomic chemotherapy was effective. It also has antiangiogenic effects when used at low doses, as it attacks the endothelial cells of tumor blood vessels. However, three of the patients in this study did not show diminished CEPs cell levels after oral UFUR. In late-stage cancer patients, multiple confounders accompanying the disease might change the number of CEP cells, including inflammation 29 and an individual's immune response to chemotherapy. 30 That increase had already started a few hours to several months after chemotherapy. 27 The relatively small number of patients in this study represents an important limitation, and hence the present findings need to be confirmed in a study with more OSCC patients.
In conclusion, the results of this study demonstrate that low-dose orally administered UFUR is beneficial to patients with advanced OSCC who have undergone resection. In addition to having lower toxicity, low-dose orally administered UFUR results in higher survival rates among OSCC patients. The number of viable CEP cells is reduced after treatment, indicating an inhibition of endothelial cell growth and angiogenesis. We therefore conclude that orally administered UFUR can serve as an effective postoperative adjuvant therapy for high-risk and advanced OSCC patients.
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